Direct oral anticoagulants (DOACs) are attractive options for treatment of heparin-induced
thrombocytopenia (HIT). We report our continuing experience in Hamilton, ON, Canada …

Many drugs have been implicated in drug-induced immune thrombocytopenia (DITP).
Patients with DITP develop a drop in platelet count 5 to 10 days after drug administration …

Several therapeutic agents can cause thrombocytopenia by either immune-mediated or non-
immune-mediated mechanisms. Non-immune-mediated thrombocytopenia is due to direct …

Extracorporeal membrane oxygenation (ECMO) is a salvage therapy for critically ill patients.
Although ECMO is becoming more common, hemorrhagic and thromboembolic …

Heparin‐induced thrombocytopenia (HIT) is a rare, potentially life‐threatening condition
secondary to unfractionated heparin or low molecular weight heparin exposure. This …

Direct oral anticoagulants have been shown safe and effective in the treatment of pulmonary
emboli and deep vein thrombi. Their role in the treatment of patients with hypercoagulability …

To review the use of the novel oral anticoagulant (NOAC) agents for the treatment of heparin-
induced thrombocytopenia (HIT) from relevant clinical trial data. A MEDLINE, International …

Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct
activated factor X inhibitors) are increasingly being used in clinical practice. Compared with …

Heparin-induced thrombocytopenia (HIT) may be a critical condition in intensive care
patients. Diagnosis of HIT is often difficult, and management too, as physicians have usually …

Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with
thrombosis (HITT) are rare but potentially limb-and life-threatening complications of heparin …